Sun Pharma Gains 2% on US Launch of LEQSELVI After Patent Settlement

Sun Pharma shares rose 2% to ₹1,711 on July 15 after settling a patent dispute with Incyte, allowing immediate US launch of LEQSELVI for alopecia areata. The deal includes upfront and royalty payments, and both parties will dismiss ongoing litigation. Morgan Stanley maintained its 'Overweight' rating with a ₹1,960 target price, citing strong sales prospects.